Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial

The Lancet

Volumn 374, Issue 9707, 2009, Pages 2080-2089

  Jaffar, Shabbar ^a   Amuron, Barbara ^b   Foster, Susan ^c   Birungi, Josephine ^d   Levin, Jonathan ^b   Namara, Geoffrey ^b   Nabiryo, Christine ^d   Ndembi, Nicaise ^b   Kyomuhangi, Rosette ^b   Opio, Alex ^e   Bunnell, Rebecca ^f   Tappero, Jordan W ^f   Mermin, Jonathan ^f   Coutinho, Alex ^g   Grosskurth, Heiner ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d THE AIDS SUPPORT ORGANIZATION   (Uganda)

^e MINISTRY OF HEALTH   (Uganda)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g MULAGO HOSPITAL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAIL PIGMENTATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; TREATMENT FAILURE; TREATMENT RESPONSE; UGANDA; UNSPECIFIED SIDE EFFECT; URBAN AREA; VOMITING;

EID: 72149133645     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61674-3     Document Type: Article

References (32)

1. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Report by the Secretariat (2008), WHO, Geneva
2. United Nations General Assembly. Political Declaration on HIV/AIDS (2006), United Nations, New York. http://www.unaids.org/en/AboutUNAIDS/Goals/UNGASS (accessed May 1, 2009).
3. WHO. The World Health Report: primary care now more than ever (2008), WHO, Geneva
4. Hardon A.P., Akurut D., Comoro C., et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19 (2007) 658-665
5. Ware N.C., Idoko J., Kaaya S., et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 6 (2009) e11
6. WHO. Treat, train, retain. Task shifting: global recommendations and guidelines (2007), WHO, Geneva
7. Gilks C.F., Crowley S., Ekpini R., et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006) 505-510
8. Ferradini L., Jeannin A., Pinoges L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 (2006) 1335-1342
9. Harries A.D., Schouten E.J., and Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 367 (2006) 1870-1872
10. Stringer J.S., Zulu I., Levy J., et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 (2006) 782-793
11. Gimbel-Sherr S.O., Micek M.A., Gimbel-Sherr K.H., et al. Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health 5 (2007) 7
12. Miles K., Clutterbuck D.J., Seitio O., Sebego M., and Riley A. Antiretroviral treatment roll-out in a resource-constrained setting: capitalizing on nursing resources in Botswana. Bull World Health Organ 85 (2007) 555-560
13. Bedelu M., Ford N., Hilderbrand K., and Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 196 suppl 3 (2007) 464-468
14. Rosen S., Fox M.P., and Gill C.J. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4 (2007) e298
15. Zachariah R., Ford N., Philips M., et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg 103 (2009) 549-558
16. Mermin J., Were W., Ekwaru J.P., et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 371 (2008) 752-759
17. Weidle P.J., Wamai N., Solberg P., et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368 (2006) 1587-1594
18. Amuron B., Coutinho A., Grosskurth H., et al. A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J 1 (2007) 21-27
19. Jaffar S., Amuron B., Birungi J., et al. Integrating research into routine service delivery in an antiretroviral treatment programme: lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda. Trop Med Int Health 13 (2008) 795-800
20. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20 (2006) 1391-1399
21. Coetzee D., Hildebrand K., Boulle A., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18 (2004) 887-895
22. Laurent C., Diakhate N., Gueye N.F., et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16 (2002) 1363-1370
23. WHO. International Statistical Classification of Diseases and Related Health Problems, 10th revision, version for (2007). http://apps.who.int/classifications/apps/icd/icd10online (accessed Aug 10, 2009).
24. Etard J.F., Ndiaye I., Thierry-Mieg M., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20 (2006) 1181-1189
25. Marazzi M.C., Liotta G., Germano P., et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 24 (2008) 555-560
26. Toure S., Kouadio B., Seyler C., et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22 (2008) 873-882
27. Braitstein P., Brinkhof M.W., Dabis F., et al., for the Antiretroviral Therapy in Lower Income Countries Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
28. Fielding K.L., Charalambous S., Stenson A.L., et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 8 (2008) 93
29. Lawn S.D., Harries A.D., Anglaret X., Myer L., and Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 (2008) 1897-1908
30. Medina-Lara A., Kigozi J., Amurwon J., et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention Cape Town. International AIDS Society, 2009. http://www.ias2009.org/pag/Abstracts.aspx?AID=3830 (accessed July 1, 2009).
31. Amuron B., Namara G., Birungi J., et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 9 (2009) 290
32. Jaffar S., Leach A., Hall A.J., et al. Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation?. Vaccine 18 (1999) 633-640